182 related articles for article (PubMed ID: 35111167)
1. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
Keret S; Henig I; Zuckerman T; Kaly L; Shouval A; Awisat A; Rosner I; Rozenbaum M; Boulman N; Dortort Lazar A; Molad Y; Sabbah F; Naffaa ME; Hardak E; Slobodin G; Rimar D
Rheumatology (Oxford); 2024 May; 63(6):1534-1538. PubMed ID: 37672021
[TBL] [Abstract][Full Text] [Related]
3. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis.
Del Papa N; Pignataro F; Zaccara E; Maglione W; Minniti A
Front Immunol; 2018; 9():2390. PubMed ID: 30386340
[TBL] [Abstract][Full Text] [Related]
4. Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients.
Strunz PP; Froehlich M; Gernert M; Schwaneck EC; Fleischer A; Pecher AC; Tony HP; Henes JC; Schmalzing M
Front Immunol; 2021; 12():723349. PubMed ID: 34539659
[TBL] [Abstract][Full Text] [Related]
5. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.
Shouval R; Furie N; Raanani P; Nagler A; Gafter-Gvili A
Biol Blood Marrow Transplant; 2018 May; 24(5):937-944. PubMed ID: 29374527
[TBL] [Abstract][Full Text] [Related]
6. Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis.
Boukouaci W; Lansiaux P; Lambert NC; Picard C; Clave E; Cras A; Marjanovic Z; Farge D; Tamouza R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806227
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review.
Puyade M; Maltez N; Lansiaux P; Pugnet G; Roblot P; Colmegna I; Hudson M; Farge D
Rheumatology (Oxford); 2020 Apr; 59(4):779-789. PubMed ID: 31504944
[TBL] [Abstract][Full Text] [Related]
8. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease.
Strunz PP; Labinsky H; Nagler LK; Portegys J; Froehlich M; Gernert M; Schmalzing M
Front Immunol; 2023; 14():1294496. PubMed ID: 38045701
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern.
Gernert M; Tony HP; Schwaneck EC; Gadeholt O; Schmalzing M
Arthritis Res Ther; 2019 Apr; 21(1):106. PubMed ID: 31036055
[TBL] [Abstract][Full Text] [Related]
11. Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome.
Pecher AC; Klein R; Koetter I; Wagner M; Vogel W; Wirths S; Lengerke C; Henes JC
Arthritis Res Ther; 2024 Mar; 26(1):75. PubMed ID: 38509633
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.
Gressenberger P; Jud P; Kovacs G; Kreuzer S; Brezinsek HP; Guetl K; Muster V; Kolesnik E; Schmidt A; Odler B; Adelsmayr G; Neumeister P; Brcic L; Zenz S; Weber K; Gary T; Brodmann M; Graninger WB; Moazedi-Fürst FC
J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34201939
[TBL] [Abstract][Full Text] [Related]
13. Stem cell transplantation for systemic sclerosis.
Bruera S; Sidanmat H; Molony DA; Mayes MD; Suarez-Almazor ME; Krause K; Lopez-Olivo MA
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011819. PubMed ID: 35904231
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary mucormycosis following autologous hematopoietic stem cell transplantation for rapidly progressive diffuse cutaneous systemic sclerosis: A case report.
Boumaza X; Lelièvre L; Guenounou S; Borel C; Huynh A; Beziat G; Delavigne K; Guinault D; Garric M; Piel-Julian M; Paricaud K; Moulis G; Astudillo L; Sailler L; Farge D; Pugnet G
Medicine (Baltimore); 2020 Jul; 99(31):e21431. PubMed ID: 32756151
[TBL] [Abstract][Full Text] [Related]
15. Overlapping Case of Advanced Systemic Sclerosis and IgG4-Related Disease after Autologous Hematopoietic Stem Cell Transplantation.
Dulko AJ; Butrimiene I; Cypiene A; Peceliunas V; Petroska D; Stankeviciene E; Rugiene R
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541223
[TBL] [Abstract][Full Text] [Related]
16. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
17. Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients.
Zanin-Silva DC; Santana-Gonçalves M; Kawashima-Vasconcelos MY; Lima-Júnior JR; Dias JBE; Moraes DA; Covas DT; Malmegrim KCR; Ramalho L; Oliveira MC
Arthritis Res Ther; 2022 Apr; 24(1):95. PubMed ID: 35488348
[TBL] [Abstract][Full Text] [Related]
18. Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation.
Gernert M; Tony HP; Schwaneck EC; Fröhlich M; Schmalzing M
Arthritis Res Ther; 2020 Aug; 22(1):183. PubMed ID: 32771029
[TBL] [Abstract][Full Text] [Related]
19. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.
Arruda LCM; Malmegrim KCR; Lima-Júnior JR; Clave E; Dias JBE; Moraes DA; Douay C; Fournier I; Moins-Teisserenc H; Alberdi AJ; Covas DT; Simões BP; Lansiaux P; Toubert A; Oliveira MC
Blood Adv; 2018 Jan; 2(2):126-141. PubMed ID: 29365321
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
